DE602005026814D1 - Einfügen von Transgenen in adenovirale Vektoren - Google Patents

Einfügen von Transgenen in adenovirale Vektoren

Info

Publication number
DE602005026814D1
DE602005026814D1 DE602005026814T DE602005026814T DE602005026814D1 DE 602005026814 D1 DE602005026814 D1 DE 602005026814D1 DE 602005026814 T DE602005026814 T DE 602005026814T DE 602005026814 T DE602005026814 T DE 602005026814T DE 602005026814 D1 DE602005026814 D1 DE 602005026814D1
Authority
DE
Germany
Prior art keywords
sites
adenoviral vectors
signals
inserting transgenes
processing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026814T
Other languages
English (en)
Inventor
Lynda Hawkins
Reddy Police Seshidar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosante Pharmaceuticals Inc
Original Assignee
Biosante Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosante Pharmaceuticals Inc filed Critical Biosante Pharmaceuticals Inc
Publication of DE602005026814D1 publication Critical patent/DE602005026814D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Image Processing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
DE602005026814T 2004-07-22 2005-07-21 Einfügen von Transgenen in adenovirale Vektoren Active DE602005026814D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58980404P 2004-07-22 2004-07-22
US66054205P 2005-03-11 2005-03-11
PCT/US2005/025833 WO2006012393A2 (en) 2004-07-22 2005-07-21 Addition of transgenes into adenoviral vectors

Publications (1)

Publication Number Publication Date
DE602005026814D1 true DE602005026814D1 (de) 2011-04-21

Family

ID=35786690

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026814T Active DE602005026814D1 (de) 2004-07-22 2005-07-21 Einfügen von Transgenen in adenovirale Vektoren

Country Status (7)

Country Link
US (1) US20060292682A1 (de)
EP (1) EP1771570B1 (de)
JP (1) JP2008507279A (de)
AT (1) ATE501262T1 (de)
CA (1) CA2574698A1 (de)
DE (1) DE602005026814D1 (de)
WO (1) WO2006012393A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078140A2 (en) 2003-03-05 2004-09-16 Halozyme, Inc. SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US7709224B2 (en) * 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7632509B2 (en) 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
EP2268129B1 (de) * 2008-04-21 2015-06-17 Danziger Innovations Ltd. Virale expressionsvektoren aus pflanzen und ihre verwendung zur erzeugung genotypischer variationen bei pflanzengenomen
US9206440B2 (en) 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2011014794A1 (en) * 2009-07-31 2011-02-03 Paxvax, Inc. Adenoviral-based vectors
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
WO2012003287A2 (en) * 2010-06-30 2012-01-05 The Johns Hopkins University Compositions and methods for detecting and quantifying circulating tumor cells ctcs
US9540657B2 (en) * 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
EP2971008B1 (de) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Onkolytische adenoviruszusammensetzungen
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
RS57043B1 (sr) 2013-10-25 2018-05-31 Psioxus Therapeutics Ltd Onkolitički adenovirusi snabdeveni heterologus genima
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201415344D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Protein
WO2016084084A1 (en) 2014-11-27 2016-06-02 Danziger Innovations Ltd. Nucleic acid constructs for genome editing
BR112017023171A2 (pt) 2015-04-30 2018-07-17 Psioxus Therapeutics Limited adenovírus oncolítico que codifica proteína b7
EA201891021A1 (ru) 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
NZ759833A (en) * 2017-05-26 2023-01-27 Epicentrx Inc Recombinant adenoviruses carrying transgenes
GB202013834D0 (en) 2020-09-03 2020-10-21 Valo Therapeutics Oy PeptiVAX therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518913A (en) * 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US20050175589A1 (en) * 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AU2002346084B2 (en) * 2001-07-23 2006-11-16 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
WO2003072703A2 (en) * 2002-02-05 2003-09-04 Cornell Research Foundation, Inc. Adenoviral vector with replication-dependent transgene expression
US20040213764A1 (en) * 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail

Also Published As

Publication number Publication date
US20060292682A1 (en) 2006-12-28
WO2006012393A3 (en) 2006-09-21
EP1771570A4 (de) 2008-03-26
CA2574698A1 (en) 2006-02-02
ATE501262T1 (de) 2011-03-15
WO2006012393A2 (en) 2006-02-02
JP2008507279A (ja) 2008-03-13
EP1771570A2 (de) 2007-04-11
EP1771570B1 (de) 2011-03-09

Similar Documents

Publication Publication Date Title
DE602005026814D1 (de) Einfügen von Transgenen in adenovirale Vektoren
CA3033327A1 (en) Programmable cas9-recombinase fusion proteins and uses thereof
EA200200960A1 (ru) Промоторы вируса желтого скручивания листьев цестровых
WO2007136865A3 (en) Recombinant vectors
DE60144248D1 (de) Verfahren zur klonierung von nichtmenschliche säugern unter verwendung von reprogrammiertem donorchromatin oder donorzellen
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
DK2152880T3 (da) Sammensætninger og fremgangsmåder til hæmning af endogene immunoglobulingener og produktion af transgene, humane idiotype antistoffer
WO2000053724A3 (en) Compositions and methods for the modification of gene transcription
MX2010003369A (es) Regiones no traducidas 5' sinteticas, vectores de expresion y metodos para incrementar la expresion transgenica.
DE60236182D1 (de) Zufällige integration von polynukleotide nach in vivo linearisierung
ATE512228T1 (de) Induzierbare expressionssysteme
DE602004030315D1 (de) Induzierbare sirna expressionskonstrukte zur gezielten genabschaltung
WO2003087313A3 (en) Enhanced silk exsertion under stress
TNSN07295A1 (en) Nucleic acid constructs
EA202090661A1 (ru) Мутантные гены протопорфириноген ix оксидазы (ppx)
WO2006013103A3 (de) Induzierbare genexpression
MX2009006681A (es) Composiciones y metodos para la expresion de acidos nucleicos.
ATE406094T1 (de) Identifizierung und charakterisierung von genen
DE60042396D1 (de) Hohe expression eines heterologen proteins mit seltenen codons
MX2022004107A (es) Celulas con expresion transgenica sostenida.
ATE334592T1 (de) Biologische bekämpfung von nematoden
ATE342998T1 (de) Replikation -defektive baculoviren expressionssystem
ATE451450T1 (de) Promotoren von bananen und melonen zur expression von transgenen in pflanzen
DE60042922D1 (de) Virale expressionsvektoren für pflanzen
DE50214936D1 (de) Verwendung des adenoviralen e2-late-promotors